Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues

Author's Avatar
Nov 17, 2022
  • First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery
  • No venous ulcer recurrences or CVI relapses
  • Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS)